Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.58 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | DGAT2 | Q96PD7 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739756 | 1.00 | UCHL1 (0.58) | UCHL1ABHD6HTR1AHTR7SCN9A | |
| SCHEMBL17010293 | 0.89 | UCHL1 (0.60) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL30519105 | 0.89 | UCHL1 (0.60) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL15271994 | 0.86 | SCN9A (0.52) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL15272482 | 0.85 | SCN9A (0.52) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL17010302 | 0.85 | ABHD6 (0.56) | UCHL1ABHD6HTR1AHTR7SCN9A | |
| SCHEMBL3275497 | 0.83 | MAPK1 (0.42) | UCHL1ABHD6HTR1AHTR7SCN9A | |
| SCHEMBL15272213 | 0.82 | SCN9A (0.53) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL17021260 | 0.82 | UCHL1 (0.56) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL29739744 | 0.82 | UCHL1 (0.56) | UCHL1ABHD6SCN9ASCN5AESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-12-31 | — | — | US | disclosed |
| US-10738026-B2 | Isoquinoline derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3105217-B1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-03-02 | — | — | US | disclosed |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-03-02 | — | — | US | disclosed |
| WO-2015123398-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738026-B2 | Isoquinoline derivatives and use thereof | KCNQ3, KCNQ5, KCNQ4 | UCHL1 3538/4885ABHD6 3395/4885HTR1A 413/4885 |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | UCHL1 3538/4885ABHD6 3395/4885HTR1A 413/4885 |
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | UCHL1 3538/4885ABHD6 3395/4885HTR1A 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.